Search PubMed⌕ Search

Biomedical subjects

I Harrison

Publications and source records attributed to I Harrison.

27 records · Page 2Linked to original sources

Treatment of hygromata in horses.

A surgical technique of open drainage, using penrose drains and pressure bandages, was used for the treatment of hygromata in four horses. In 3 cases with hygroma of the carpus, one with a secondary infection, there was complete resolution of the condition whereas in the one case with hygroma of the elbow resolution was more protracted because of difficulties in bandaging. The cosmetic and functional results after operation were most satisfactory.

Animals↗

Spironolactone and canrenoate-K: relative potency at steady state.

Relative dose ratios of the mineralocorticoid antagonists spironolactone (100 mg and 200 mg daily) and canrenoate-K (200 mg daily) at steady state were defined in six healthy subjects with fludrecortisone as the mineralocorticoid agonist. The urine log 10 Na/K responses during spironolactone treatments were consistent with the law of mass action. The potency of canrenoate-K was 0.68 (95% C.L. 0.53 to 0.89) that of spironolactone on a weight basis. Approximately 72% of the renal antimineralocorticoid activity of spironolactone could attributed to the metabolite canrenone. The results at steady state are contrasted with those of a previously study comparing single doses of spironolactone and canrenoate-K.

Administration, Oral↗

Spironolactone and potassium canrenoate in normal man.

The pharmacological activity of single doses of the two aldosterone antagonists, potassium canrenoate and spironolactone, was examined in two studies in healthy volunteers. Both drugs were active in reversing urinary electrolyte changes induced by fludrocortisone in periods 2 to 16 hr after treatment. Potassium canrenoate was significantly less potent that spironolactone on a weight or molar basis, with best estimates of the relative potency potassium canrenoate: spironolactone of approximately 0.3:1. On a weight basis the two drugs yielded plasma levels of the metabolite canrenone which were approximately equivalent. The results indicate that canrenone is not the principal pharmacologically active metabolite of spironolactone. Our study suggests that a major part of the renal antimineralocorticoid activity of spironolactone may be attributable to minor sulfur-containing metabolites or their precursors having a high renal clearance that affords access to their site of activity via the renal tubular fluid.

Canrenoic Acid↗

Massive bleeding from the pharyngoesophageal diverticulum.

A case of massive upper gastrointestinal bleeding secondary to an ulcer within a Zenker's diverticulum is presented. The possible causes of the bleeding have been discussed, but the topical effect of aspirin intake appears to be the cause of bleeding in this case.

Aspirin↗

Relative potency of prorenoate and spironolactone in normal man.

The potency of single doses of a new aldosterone antagonist, prorenoate, in reversing the renal effects of the synthetic mineralocorticoid fludrocortisone was compared to that of spironolactone in a double-blind balanced crossover study in 12 healthy subjects. The potency of prorenoate potassium as related to elevation of the urinary log 10 10 Na/K ratio (2.69:1) and as related to potassium retention (3.75:1) was significantly higher than that of spironolactone. Prorenoate produced greater natriuresis (1.64:1) but the difference was not significant. There was evidence for a qualitative difference between spironolactone and prorenoate; the latter significantly more potent in retaining potassium than in increasing sodium excretion. The simple methodology described is based on standard bioassay principles, yielded a valid and sensitive comparison of the two drugs, and should prove useful in the evaluation of other aldosterone antagonists.

Adolescent↗

Adaptable pharmacy.

Explore the source record for details and available documents.

Humans↗